Emergent BioSolutions Inc. (NYSE: EBS) today announced it has secured a contract award valued at approximately $54 million USD to deliver CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV ...

Analysts have reset their price target on Emergent BioSolutions to US$12 from US$15, keeping the fair value estimate at US$12 ...

Emergent BioSolutions was awarded a contract worth about $54 million to supply the Administration for Strategic Preparedness and Response with additional doses of Vigiv, a treatment for smallpox ...

Artis BioSolutions ("Artis"), an advanced therapies company dedicated to integrating the specialized technologies, ...

Emergent Biosolutions (NYSE:EBS) reported fourth-quarter and full-year 2025 results on a Feb. 26, 2026 earnings call, with ...

Emergent BioSolutions Inc. (NYSE:EBS) shares rose 4.5% in after-hours trading Wednesday following the announcement of a $54 ...

In addition to OEM distribution, the collaboration provides flexibility for potential future expansion, which could include Dyadic supplying market-ready products for distribution or licensing ...

Emergent BioSolutions (NYSE:EBS) stock is trading higher on Thursday after the company announced the sale of its facility in Baltimore-Camden to Bora Pharmaceuticals. What Happened: On Thursday prior ...

Emergent BioSolutions Inc. (NYSE: EBS) today announced it has secured a contract award valued at approximately $54 million USD to deliver CNJ-016® ...

Artis BioSolutions Establishes U.S.-based Synthetic DNA Manufacturing Hub in Boston Share Expanded facility integrates Syngoi Technologies’ enzymatic DNA platform into Artis’ North American operations ...